HUTCHMED Entered into an Exclusive License Agreement with Takeda to Develop and Commercialize Fruquintinib
Shots:
- HUTCHMED to receive ~$1.13B incl. $400M up front, ~$730M in regulatory, development & commercial sales milestones along with royalties. The agreement strengthens Takeda’s oncology portfolio
- Takeda to receive an exclusive license globally to develop & commercialize fruquintinib in all indications & territories outside of mainland China, Hong Kong & Macau. In collaboration with Eli Lilly, HUTCHMED focuses on late-stage clinical trials & commercialization of fruquintinib in mainland China, approved under the brand name Elunate
- The marketing authorization submissions in the US, EU & Japan are planned to complete in 2023 with rolling submission to the US FDA in H1’23. The P-III trial (FRESCO-2) results of fruquintinib for refractory CRC were presented at ESMO 2022
Ref: Businesswire | Image: HUTCHMED
Related News:- HUTCHMED Presents P-III (FRESCO-2) MRCT Study Results of Fruquintinib for Refractory Metastatic Colorectal Cancer at ESMO 2022
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
